Article, News
Prescient (ASX:PTX) closes a very productive September quarter, achieving key milestones
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published its report for the September quarter. The company sees the…
Article, News
ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it…
Article, News
Prescient’s (ASX:PTX) PTX-100 demonstrates encouraging clinical activity in T cell lymphomas
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical activity of PTX-100, one of the targeted therapies of Prescient. PTX-100…
Article, News
Prescient Therapeutics PTX-100 continues to exhibit excellent safety profile
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient shows that PTX-100 is safe and effective on difficult to treat T-cell lymphomas
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient Therapeutics’ PTX-100 expansion cohort continues to deliver on safety and clinical movement
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion cohort targeting relapsed and refractory T cell lymphoma (TCL) – and…
Article, News
Prescient Therapeutics reports positive safety data from PTX-100 study on T-cell lymphoma patients
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity…
Article, News
Prescient Therapeutics A$2.5 million top-up placement brings raise total to A$11.3 million
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater for strong investor demand. Late last week, the clinical-stage oncology…
Article, News
Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.
Article, News
Prescient Therapeutics at forefront of overcoming challenges, with game-changing CAR-T cell cancer therapies
CAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies it is not without problems, which Prescient Therapeutics…